The Baltics: a region punching above its weight on the global life sciences stage
Once best-known on the world stage as a country with a rich basketball history, a sport so deeply ingrained in…
All articles by Ross Law
Ross Law
Ross Henry Law is a reporter for Medical Device Network. His key interest areas in healthcare include regulation, mental health, neurology, oncology, and Alzheimer's disease. Ross also has extensive prior experience in covering the captive insurance, retail, and technology sectors.
-
-
European PE company prioritising CGT and other novel modality investments
Mérieux Equity Partners (MxEP) has outlined its approach to investing in Lithuania and wider Europe, highlighting a particular focus on…
-
Innovative mental health treatment tech struggles for traction as pharma dominates
While tools from digital therapeutics to neuromodulation headsets to address mental health conditions are being developed, such offerings have not…
-
Magazine: China’s CGT edge
The cell and gene therapy (CGT) space continues to generate a lot of buzz. Amid ongoing funding challenges and getting clinical…
-
Magazine: Big biopharma take on the ADC challenge
Antibody‑drug conjugates (ADCs) remain an area of extreme focus in the pharmaceuticals space, with the market projected to hit a…
-
Accelerating diagnosis and drug development with better managed datasets
Every aspect of science and research is based on data, and across the globe, labs are producing more data than…
-
A new way forward in ovarian cancer: why synthetic iMSCs could change the paradigm
Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is still…
-
EpiPen patent expiry opens new era for innovation
The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery…
-
UK-India $4.8bn FTA poised to benefit medtech and pharma
The UK and India’s newly signed £4.8bn ($6.45bn) free trade agreement (FTA) is expected to give rise to new opportunities…
-
Life sciences VC Omega Funds closes $647m funding round
Life sciences venture capital (VC) company Omega Funds has closed its eighth fund, with capital commitments totalling $647m. As with…